SDZ-DJN 608
SDZ-DJN 608 Brand names, SDZ-DJN 608 Analogs
SDZ-DJN 608 Brand Names Mixture
- No information avaliable
SDZ-DJN 608 Chemical_Formula
C19H27NO3
SDZ-DJN 608 RX_link
http://www.rxlist.com/cgi/generic2/nateglinide.htm
SDZ-DJN 608 fda sheet
SDZ-DJN 608 msds (material safety sheet)
SDZ-DJN 608 Synthesis Reference
No information avaliable
SDZ-DJN 608 Molecular Weight
317.423 g/mol
SDZ-DJN 608 Melting Point
No information avaliable
SDZ-DJN 608 H2O Solubility
Practically insoluble
SDZ-DJN 608 State
Solid
SDZ-DJN 608 LogP
3.824
SDZ-DJN 608 Dosage Forms
Tablets (60, 120 mg)
SDZ-DJN 608 Indication
For use as monotherapy to lower blood glucose in patients with Type 2 diabetes (non-insulin dependent diabetes mellitus, NIDDM) whose hyperglycemia cannot be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents. Also indicated for use in combination with metformin.
SDZ-DJN 608 Pharmacology
Nateglinide is an amino-acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets.
SDZ-DJN 608 Absorption
Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%.
SDZ-DJN 608 side effects and Toxicity
An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.
SDZ-DJN 608 Patient Information
SDZ-DJN 608 Organisms Affected
Humans and other mammals
